Healthcare Industry News: rNAPc2
News Release - March 23, 2006
Nuvelo Appoints Shelly D. Guyer Vice President, Business Development and Investor RelationsSAN CARLOS, Calif., March 23 (HSMN NewsFeed) -- Nuvelo Inc. (Nasdaq: NUVO ) today announced the appointment of Shelly D. Guyer as vice president, business development and investor relations. Ms. Guyer, who has more than 18 years of experience in healthcare banking and management, joins Nuvelo as a member of the management team and will be responsible for leading the business development and investor relations activities at Nuvelo.
"Shelly brings exceptional healthcare investment banking experience and a unique perspective to Nuvelo having led deals and financings for leading companies in the biopharmaceutical industry," said Dr. Ted W. Love, chairman and chief executive officer of Nuvelo. "Shelly joins us at an exciting time as we move forward in our collaboration with Bayer HealthCare and prepare to expand several of our development programs, including alfimeprase in stroke and deep venous thrombosis (DVT), and rNAPc2 in cancer. We are pursuing additional partnership opportunities to fully exploit our entire pipeline of potential cardiovascular and cancer therapeutics, and Shelly's expertise will be invaluable in helping us to drive these efforts."
Ms. Guyer joins Nuvelo from JPMorgan Securities, where she most recently served as vice president of Health Care Banking for the West Coast and was responsible for financings for a variety of large and small cap life science companies. During the acquisition of H&Q by Chase and the merger with JPMorgan, Ms. Guyer served in several internal capacities for the Investment Banking Division. Prior to that, she was vice president and principal in Investment Banking at Hambrecht & Quist.
Ms. Guyer received an M.B.A. from the Walter A. Haas School of Business at the University of California, Berkeley, and a B.A., summa cum laude from Princeton University.
Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes three acute cardiovascular programs focused on alfimeprase, a direct-acting thrombolytic in Phase 3 clinical trials for the treatment of thrombotic- related disorders; rNAPc2, an anticoagulant that inhibits the factor VIIa and tissue factor protease complex that is currently in Phase 2 clinical development for acute coronary syndromes and a thrombin inhibiting aptamer for anticoagulation during medical procedures. Nuvelo is also progressing an emerging oncology pipeline, which includes NU206, for the potential treatment of chemotherapy/radiation therapy-induced mucositis, as well as rNAPc2 for potential use as a cancer therapy. In addition, Nuvelo expects to leverage its expertise in secreted proteins and cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities. Information about Nuvelo is available at our website at www.nuvelo.com or by phoning 650-517-8000.
This press release contains "forward-looking statements" regarding the progress of our clinical development programs, the progress of our collaboration with Bayer HealthCare, and our success in concluding additional collaborations, which statements are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on our management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward looking statements as a result of many factors, including, without limitation, uncertainties relating to drug discovery; clinical development processes; enrollment rates for patients in our clinical trials; changes in relationships with strategic partners and dependence upon strategic partners for the performance of critical activities under collaborative agreements; and the impact of competitive products and technological changes. These and other factors are identified and described in more detail in Nuvelo filings with the SEC, including without limitation Nuvelo's recent annual report on Form 10-K for the year ended December 31, 2005 and subsequent filings. We disclaim any intent or obligation to update these forward-looking statements.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.